Molecular Imaging of HER2 Receptor: Targeting HER2 for Imaging and Therapy in Nuclear Medicine

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2023 Mar 20

PMID 36936995

Authors

Daniela Miladinova

Affiliations

Soon will be listed here.

Abstract

Targeting HER 2 for imaging and therapy in nuclear medicine has been used with a special emphasis on developing more powerful radiopharmaceuticals. Zirconium-89 plays an essential role in immune PET imaging so was used labeled with anti-HER2 antibody (Trastuzumab and Pertuzumab). Also there were attempts with other PET tracers as Cuprum-64 and Galium-68, as well as SPECT radiopharmaceuticals Indium-111 and Technetium- 99m. Regarding antibody pharmacokinetic that is not quite appropriate for imaging acquisition, several smaller molecules with shorter residence times have been developed. These molecules called nanobody, affibody, minibody do not compromize HER2 receptor affinity and specificity. Excess of Trastuzumab do not block the affinity of labeled affibodies. Silica nanoparticles have been conjugated to anti-HER2 antibodies to enable targeting of HER2 expressing cells with potential of drug delivery carry for antitumor agents and b(beta) or a(alfa) emitting radioisotopes commonly used for radionuclide therapy, as Iodine-131, Lutetium-177, Yttrium-90, Rhenium-188 and Thorium-277.

Citing Articles

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E Breast Cancer Res. 2024; 26(1):140.

PMID: 39375745 PMC: 11459983. DOI: 10.1186/s13058-024-01899-2.

Radiosynthesis and preclinical evaluations of [F]AlF-RESCA-5F7 as a novel molecular probe for HER2 tumor imaging.

Tian R, Kong J, He Y, Xu G, Chen T, Han J Am J Nucl Med Mol Imaging. 2024; 14(3):175-181.

PMID: 39027646 PMC: 11253080. DOI: 10.62347/BVPK1360.

RNA nanostructures for targeted drug delivery and imaging.

Teodori L, Omer M, Kjems J RNA Biol. 2024; 21(1):1-19.

PMID: 38555519 PMC: 10984137. DOI: 10.1080/15476286.2024.2328440.

Evaluation of chicken chorioallantoic membrane model for tumor imaging and drug development: Promising findings.

Wang L, Yan J, XinyuWang , Xu Y, Pan D, Chen C Animal Model Exp Med. 2024; 8(2):287-294.

PMID: 38230452 PMC: 11871095. DOI: 10.1002/ame2.12380.

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.

Ascione L, Crimini E, Trapani D, Marra A, Criscitiello C, Curigliano G Oncologist. 2023; 28(11):944-960.

PMID: 37665782 PMC: 10628585. DOI: 10.1093/oncolo/oyad246.

References

Ulaner G, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S . Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med. 2016; 57(10):1523-1528. PMC: 5050126. DOI: 10.2967/jnumed.115.172031. View

Mitri Z, Constantine T, ORegan R . The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2013; 2012:743193. PMC: 3539433. DOI: 10.1155/2012/743193. View

Zaha D . Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014; 5(3):382-92. PMC: 4127609. DOI: 10.5306/wjco.v5.i3.382. View

Schrijver W, Suijkerbuijk K, van Gils C, van der Wall E, Moelans C, van Diest P . Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018; 110(6):568-580. DOI: 10.1093/jnci/djx273. View

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y . 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013; 54(11):1869-75. DOI: 10.2967/jnumed.112.118612. View

Ulaner G, Carrasquillo J, Riedl C, Yeh R, Hatzoglou V, Ross D . Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. Radiology. 2020; 296(2):370-378. PMC: 7543717. DOI: 10.1148/radiol.2020192828. View

Dijkers E, Munnink T, Kosterink J, Brouwers A, Jager P, de Jong J . Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87(5):586-92. DOI: 10.1038/clpt.2010.12. View

Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L . Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules. 2021; 26(21). PMC: 8588233. DOI: 10.3390/molecules26216482. View

Ahn S, Woo J, Lee K, Park S . HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2019; 54(1):34-44. PMC: 6986968. DOI: 10.4132/jptm.2019.11.03. View

10.

Ulaner G, Riedl C, Dickler M, Jhaveri K, Pandit-Taskar N, Weber W . Molecular Imaging of Biomarkers in Breast Cancer. J Nucl Med. 2016; 57 Suppl 1:53S-9S. PMC: 4979972. DOI: 10.2967/jnumed.115.157909. View

11.

Iqbal N, Iqbal N . Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014:852748. PMC: 4170925. DOI: 10.1155/2014/852748. View

12.

Perik P, Lub-de Hooge M, Gietema J, van der Graaf W, de Korte M, Jonkman S . Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006; 24(15):2276-82. DOI: 10.1200/JCO.2005.03.8448. View

13.

Gu G, Dustin D, Fuqua S . Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016; 31:97-103. DOI: 10.1016/j.coph.2016.11.005. View

14.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

15.

Behr T, Behe M, Wormann B . Trastuzumab and breast cancer. N Engl J Med. 2001; 345(13):995-6. DOI: 10.1056/NEJM200109273451312. View

16.

Laforest R, Lapi S, Oyama R, Bose R, Tabchy A, Marquez-Nostra B . [Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Mol Imaging Biol. 2016; 18(6):952-959. PMC: 5096950. DOI: 10.1007/s11307-016-0951-z. View

17.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

18.

Oliveira S, Heukers R, Sornkom J, Kok R, Van Bergen en Henegouwen P . Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release. 2013; 172(3):607-17. DOI: 10.1016/j.jconrel.2013.08.298. View

19.

Richter A, Knorr K, Schlapschy M, Robu S, Morath V, Mendler C . First In-Human Medical Imaging with a PASylated Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer. Nucl Med Mol Imaging. 2020; 54(2):114-119. PMC: 7198682. DOI: 10.1007/s13139-020-00638-7. View

20.

Massicano A, Marquez-Nostra B, Lapi S . Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Mol Imaging. 2018; 17:1536012117745386. PMC: 5784567. DOI: 10.1177/1536012117745386. View